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Novel structural templates for estrogen-receptor ligands and 
prospects for combinatorial synthesis of estrogens 
Brian E Fink, Deborah S Mortensen, Shaun R Stauffer, Zachary D Aron 
and John A Katzenellenbogen 
Introduction: The development of estrogen pharmaceutical agents with 
appropriate tissue-selectivity profiles has not yet benefited substantially from the 
application of combinatorial synthetic approaches to the preparation of 
structural classes that are known to be ligands for the estrogen receptor (ER). 
We have developed an estrogen pharmacophore that consists of a simple 
heterocyclic core scaffold, amenable to construction by combinatorial methods, 
onto which are appended 3-4 peripheral substituents that embody 
substructural motifs commonly found in nonsteroidal estrogens. The issue 
addressed here is whether these heterocyclic core structures can be used to 
prepare ligands with good affinity for the ER. 
Results: We prepared representative members of various azole core structures. 
Although members of the imidazole, thiazole or isoxazole classes generally have 
weak binding for the ER, several members of the pyrazole class show good 
binding affinity. The high-affinity pyrazoles bear close conformational 
relationship to the nonsteroidal ligand raloxifene, and they can be fitted into the 
ligand-binding pocket of the ER-raloxifene X-ray structure. 
Conclusions: Compounds such as these pyrazoles, which are novel ER 
ligands, are well suited for combinatorial synthesis using solid-phase methods. 
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Introduction 
Estrogens are endocrine regulators of the vertebrate repro- 
ductive system that have important effects in many non- 
reproductive tissues as well (bone, liver, cardiovascular 
system, CNS and so on). Many estrogen pharmaceuticals. 
based on both natural and synthetic substances. have been 
developed as agents for regulating fertility, preventing and 
controlling hormone-responsive breast cancer, and meno- 
pausal hormone replacement. These subsmnces display a 
spectrum of agonist to antagonist activity that can show 
remarkable tissue and cell selectivity [ 11. 
The molecular target of estrogens is the estrogen receptor 
(ER), of which there are now known to be two subtypes, 
ER-a and ER-P, that have different patterns of tissue 
expression and somewhat different ligand-binding speci- 
ficities [2,3]. ER is a transcription factor that binds to spe- 
cific estrogen-response elements in the promoter region 
of estrogen-regulated genes and whose activ-ity is modu- 
lated by the estrogen ligands [4]. The capacity of ER- 
ligand complexes to activate gene transcription is medi- 
ated by a series of co-regulator proteins [S]. These co-reg- 
ulators have interaction functions that tether ER to the 
RNA polymerase II preinitiation complex and enzymatic 
activities to modify chromatin structure [6]. It is the fact 
that each cell and each gene presents to an ER(subtype)- 
ligand complex a unique combination of these effector 
components-various estrogen-response elements and 
co-regulators-that appears to underlie, in part, the cell 
and gene selectivity of various estrogens [7]. 
Among known ligands for ER, the natural estrogens are the 
simplest of the steroidal hormones, distinguished by their 
phenolic A-ring (Figure 1). Synthetic estrogens, especially 
those of nonsteroidal nature , generally retain a phenolic 
function (at least for those of high potency), but otherwise 
span a remarkable range of structural motifs that encom- 
pass simple acyclic core structures of various lengths and 
sizes, as well as a variety of ring-size fused and nonfused 
carbocyclic and heterocyclic systems [&IO]. It is clear from 
many decades of medicinal-chemistry investigations that 
minor changes in the structure and stereochemistry of 
these ligands can have profound effects on both their affin- 
ity and their biocharacter (i.e. the agonist versus antagonist 
balance in various tissues). Major efforts have been directed 
at optimizing ER l&and structure to obtain desired profiles 
of tissue selectivity, but, even so. the ideal profile for 
various uses has not yet been achieved [l.ll,lZ]. 
As currently explored, E:R ligdnds are, by and large, not 
well suited for synthesis using combinatorial approaches, 
because their preparation generally involves a series of 
carbon-carbon bond forming reactions that do not give 
uniformly high yields, nor are they well adapted to solid- 
phase-synthesis methods. There are two examples of the 
preparation of estrogen combinatorial libraries on solid 
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Figure 1 
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Examples of ligands with high affinity for the 
estrogen receptor. In each case, the binding 
affinity relative to that of estradiol (100%) is 
given in parentheses. The compounds are 
grouped according to their activity in a 
standard rat uterine weight gain assay as 
(a) agonists, (b) mixed or selective 
agonist/antagonists or (c) pure antagonists. 
phase, both involving stilbene-like structures [13,14], but 
the application of combinatorial approaches for the prepa- 
ration of ER ligands has, so far, been limited. 
To expand possible combinatorial approaches to the syn- 
thesis of ER ligands, we have begun investigating simple 
structural motifs that might be used for the construction of 
molecules with high affinity for ER. The goal was to iden- 
tify core structures that could be readily prepared by the 
types of simple condensation reactions that typify those 
used in solid-phase combinatorial approaches for the prepa- 
ration of drug-like molecules, and from these to select 
ones that would support the development of high-affinity 
ligands for ER. 
Here, we describe the investigation of prototype 1,2- and 
1,3-azole systems as potential ligands for the ER. We 
examine the issue of whether ER hgands can be considered 
simply as an assembly of a phenol unit together with 2-3 
auxiliary peripheral groups linked together by a functionally 
inert core scaffold, or whether the core scaffold itself 
plays an integral role in ligand binding. In the process, we 
have discovered a new class of high-affinity ligands for ER, 
4-alkyl-1,3,5triarylpyrazoles, that bear an unexpected topo- 
logical resemblance to the nonsteroidal estrogen raloxifene 
and show an interesting structure-binding affinity pattern. 
Results and discussion 
Structural motifs found in estrogen-receptor ligands and 
proposed heterocyclic surrogates 
Selected examples of nonsteroidal ligands for the estrogen 
receptor are shown in Figure 1. together with an indication 
of their ER-binding affinity and their agonist (Ag) versus 
antagonist (Antag) character in a standard rat uterine weight 
gain assay. Collectively, these molecules exemplify a recog- 
nizable structural gestalt (Figure 2): a core structure (A) onto 
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Figure 2 
Second aromatic 
HO- (Substituent] 
Phenol B Chemtstty 8 Biology 
which are attached other, peripheral structural elements, a 
phenolic unit(B) that is always preserved, a second aromatic 
group (C) that is usually present, and another substituent 
(D) or two (D’), one of which might be aromatic. In the case 
of ER antagonists or mixed agonist/antagonists, one of the 
substituents generally contains a basic or polar function. 
Comparisons of the various specific manifestations of this 
basic structure (Figure 1) suggest that, to achieve high 
Table 1 
ER-binding affinity. the peripheral substituents (B-D’) 
need to be displayed in a certain geometric arrangement, 
so that they will be ‘in register’ with their corresponding 
subsites in the ligand-binding pocket in ER. It seems that 
this peripheral group ‘display function’ can be accom- 
plished by using core elements that encompass a consider- 
able structural variety. This raises the interesting question 
of whether the core element itself plays any direct role in 
ER binding or whether it serves merely as an inert mol- 
ecular scaffold whose function is simply to display these 
peripheral elements with appropriate topology. If  the latter 
is true, it should be possible to replace the core scaffold 
with a variety of other units, providing they also are able 
to display the peripheral elements with the appropriate 
geometry. Some of these core scaffolds. namely small-ring 
heterocycles, could be assembled by facile condensation 
reactions from simpler components, a situation that is 
favorable for the development of large chemical libraries of 
related compounds by combinatorial synthesis approaches. 
In Table 1 we have outlined two (out of many possible) 
manifestations of this conceptual approach, based on the 
incorporation of certain substructural motifs into 1,2- and 
Structural motifs found in ER ligands and proposed surrogates. 
Estrogen-receptor ligand Structural motif 
_____ 
Combinatorial analog (class) 
Benzestrol Ho&oH 1. -iiEI] 3,5-Diary1 pyrazoles 
N-N 
Raloxifene 
OH 
HO 
Hydroxytamoxifen 
HO 
Motif A. Homobibenzyl* 
3,5-Diary1 isoxazoles 
2,4-Diary1 imidazoles, 
thiazoles. oxazoles 
4,5-Diary1 imidazoles, 
oxazoles, thiazoles 
Motif B. Bibenzyl’ 
N-O 
,,~R* 
HO 
*These structural motifs are meant to highlight alternative atom connections between the phenol and a second aromatic substituent, without 
specific consideration of conformational factors. Structural motifs found in ER ligands and proposed surrogates. 
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Figure 3 
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5a R=H 6a R = H (68%) 
b R= Et (86%) b R = Et (63%) 
c R = Pr (79%) c R = Pr (55%) 
d R = Bu (84%) d R = Bu (46%) 
Synthesis of imidazoles 3 and 6a-d. 
1,3-azole systems. Here, the homobibenzyl motif A, exem- 
plified in the nonsteroidal ligands benzestrol and raloxifene, 
is represented in various 3,.5-diary]-1,2-azoles (pyrazoles 
and isoxazoles) and 2,4-diary]-1,3-azoles (imidazoles. thia- 
zoles and oxazoles). Similarly, the bibenzyl motif B is rep- 
resented in various 4,.5-diaryl-1,3-azoles. In each cast, the 
diazole N,N-systems (namely pyrazoles and imidazoles) can 
accommodate up to four peripheral substituents, whereas 
the N,O- and N,S-heterocycles (oxazoles. isoxazoles and 
thiazoles) are limited to three substituents. 
Synthesis of representative diary1 and triaryl 1,2- and 
1,3-azoles as potential ligands for the estrogen receptor 
lmidazoles 
The synthesis of representative symmetrical members of 
the imidazole class and their N-alkyl analogs was accom- 
plished by a well-precedented approach 1151 shown in 
Figure 3. Refluxing 4,4’-dimethoxybenzil (1) in formamide 
in the presence of para-formaldehyde afforded the 4,.5dis- 
ubstituted imidazole 2 [16]? which upon deprotcction with 
BBr, in CHzClz afforded imidazole 3 in good yield. A 
similar reaction using 4-methoxybenxaldehyde afforded the 
2>45- tri-substituted imidazole 4 [17-191 in good yield. To 
prepare tetra-substituted systems, the sodium salt of imida- 
zole 4 was alkylated with ethyl, propyl and butyl iodide, 
and then deprotected to afford free phenols 6a-d. 
Two additional, unsymmetrical, imidazoles were synthe- 
sized as outlined in Figure 4. The top reaction sequence 
illustrates the synthetic approach to N-ethyl imidazole 12 
Reaction of 4-methoxy-deoxybenzoin (7) [ZO] with bromine 
Figure 4 
- 
Me0 
Me0 
(i) EtaN, CH,CI,, r.t. 
(ii) TFA, THF, 0°C 
37% 
Me0 
Ac!k:;;,.,o&aoMe 
14 
Benzoyl chloride 
Et3N, DMAP 
F-3 + 70% f4-Y 
15 
Chemetrv & Bioloob 
Synthesis of imidazoles 12 and 17. 
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Figure 5 Figure 6 
l3r 
S 
LY ’ 1 NH2 Me0 
19 
o~:;,o+.jN&oR, / 
I 
(43%) 
\ CN 
EBr, 
CH,CI, 
c 
21a R = H, R’ = Me (81%) 
21 b R = Et, R’ = Me (85%) 
22a R = H. FI’ = H (45%) 
22b R = Et, R’ = H (58%) 
Me0 LY 
‘/ 
I 
18 Chemistry 8 Ecology 
Synthesis of thiazoles 22a and 22b. 
and a trace of AlCl, in Et@ gave a-bromoketone 8 [zl], 
which, upon reaction with sodium azide in acetone, afforded 
the corresponding azide 9. The azido-ketone 9 was treated 
with one equivalent of Et,N and imine 10 in tetrahydro- 
furan (THF). Removal of solvent and excess Ec,N fol- 
lowed by treatment of the crude intermediate Z,S-dihydro- 
Z-hydroxyimidazole with TFA in CH$l,, according to 
the procedure of Patonay and Hoffman [LX?], resulted in 
the formation of X-ethyl imidazole 11. Deprotection with 
BF,&MeZ in CH$l, produced imidazole 12 in good yield. 
The synthesis of N-aryl substituted imidazole 17 is also 
shown in Figure 4. Refluxing 4’-methoxy-a-bromo- 
butyrophenone (13) with p-anisidine in acetone gave the 
a-amino-ketone 14, which was converted into the benza- 
mide 15 upon reaction with benzoyl chloride and base. 
Cyclization with ammonium acetate in refluxing acetic 
acid afforded the 1,2,4,5 tetra-substituted imidazole 16, 
which upon deprotection with BF,3*SMeZ in (:H,CIZ 
produced the free phenol 17. 
Thiazoles 
The synthesis of representative thiazoles is shown in 
Figure 5. Thioamide 19, derived from 4-methoxybenzoni- 
trile (18) [23], was condensed with 4’-methoxy-a-bromo- 
acetophenone (20) or 4’-methoxy-a-bromobutyrophenone 
(13) in refluxing DMF to give high yields of the 2,4-dis- 
ubstituted thiazole 21a [24] or 2,4,5- tri-substituted thia- 
zole Zlb, respectively. Deprotection with BBr, afforded 
moderate yields of the free phenols ‘22a and 22b. 
Oxazoles 
Two representative oxazoles were synthesized as shown 
in Figure 6. Reaction of the lithium anion of dithiane 23 
with p-methoxybenzyl bromide gave the alkylated product 
24, which upon hydrolysis afforded 4’-methoxy-deoxy- 
benzoin (25) [ZS] in excellent yield. Conversion to the 
OMe 
97% 
NCS, AgNOB 
p-anisaldehyde 
26 
pmethoxybenzamide 
Synthesis of oxazoles 29 and 31. 
bromide 26 [26] and azide 27 was accomplished as 
described for analogous compounds 8 and 9 above. The 
azido-ketone 27 was then treated with one equivalent of 
Et,N and p-anisaldehyde. and then with TFA to afford 
oxazole 28 [27]. Oxazole 30 resulted from the condensa- 
tion of bromo-ketone 26 wirh p-methoxybenzamidc in 
refluxing toluene, analogous to the thiazole synthesis dis- 
cussed above. Deprotection of ‘28 and 30 with BFiGhlez 
gave oxazoles 29 and 31, respectively. 
Pyrazoles 
The synthesis of the pyrazoles incolves rhe condensation 
of a hydrazine with a 1,3-diketone [28]. LTsing the method 
of Beak and coworkers 1291. we obtained 1,3-diketone 33 
from the reaction of the methyl thioester 32 and lithium 
tetramethylpiperidide in good yield (Figure 7). Condensa- 
tion of the diketone with hydrazine hydrochloride or 
N-substituted hydrazine hydrochloridcs in refluxing DMF/ 
THF (3:l) afforded the 3,.5-disubstituted pyrazole 34a or 
1,3,5- tri-substituted pyrazoles 34b-d: yields were higher 
with aryl-substituted hydrazines than with hydrazine 
itself. Deprotrcrion of 34a-d with BBr, afforded the free 
phenols 35a-d in moderate yield. 
The introduction of a 4-alkyl substituent was accom- 
plished through rhe alkylation of diketone 33 with TBAF 
and ethyl iodide to afford 36 in moderate yield [X),31]. 
Attempts to increase the yield of this alkylation were 
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Figure 7 
r 
32 33 
!  
(i) TBAF, CH &lp 
(ii) Etl 
56% 
34a R = H (36%) 
34b R = CsH, (25%) 
34c R = CH&HS (43%) 
34d R = p-MeOCsH, (85%) 
35a R=H(61%) 
35b R = CsHS (58%) 
35c R = CH,CsHs (66%) 
35d R = p-HO&H, (45%) 
L 3hemistry 8 Biology 
36 37a R = H (70%) 
37b R = CsH, (89%) 
37c R = CH&HS (31%) 
37d R = p-MeOCsH, (23%) 
38a R = H (57%) 
38b R = CsHS (54%) 
38~ R = CH&HS (54%) 
38d R = p-HO&H5 (99%) 
Synthesis of pyrazoles 35a-d and 38a-d. 
unsuccessful. Conversion of diketone 36 to the corre- 
sponding pyrazoles was accomplished as with the unsub- 
stituted case, to afford pyrazoles 38a-d. 
lsoxazoles 
The preparation of a single isoxazole is shown in Figure 8 
[32]. Double deprotonation of the ketoxime 39 derived 
from 4-methoxyacetophenone with nBuLi, followed by 
addition of methyl 4-methoxybenzoate afforded the 3$dis- 
ubstituted isoxazole 40 in low yield [33]. Deprotection with 
BBr, afforded the free phenol 41 in moderate yield [34]. 
Estrogen-receptor binding 
The binding affinities of the heterocycles prepared above 
for the estrogen receptor are shown in Tables 2-4, organized 
according to heterocyclic core structure. The binding values 
were obtained from a competitive radiometric binding assay, 
using [3H]estradiol as the tracer, dextran-coated charcoal 
Figure 8 
Me0 
N/OH N-O 
(i) nBuLi (2 eq.) 
(ii) methyl 
;;R&O;y- ,,tiOR 
39 30% 
Chemistry & Bdogy 
Synthesis of isoxazole 41. 
to adsorb free tracer and lamb uterine cytosol as a source 
of ER. The values are expressed as relative binding affini- 
ties (RB14), with estradiol having an affinity of 100% [35]. 
In replicate assays, these values are reproducible with a 
coefficient of variation of 30% (K.E. Carlson and J.A.K., 
unpublished observations). 
Imidazoles, oxazoles and thiazoles 
The receptor-binding data for the imidazole series are 
shown in Table 2. Although the members of this series 
have rather low affinity, there is an increase in RBA with 
the addition of alkyl substituents at the l-position (R3; 
h-d): this trend reaches a maximum for propyl 6c, revers- 
ing for the butyl substituent 6d. Such trends, where affinity 
Table 2 
Estrogen receptor binding data for imidazoles 8,6e-d, 12 and 17. 
R2 ,R3 
,1-t&,4 
Compound R1 R2 R3 R4 RBA’ 
3 4’-HO-&H, 4’-HO-&H, H H <O.OOl 
6a 4’-HO-&H, 4’sHO-&H, H 4’.HO-&H, 0.007 
6b 4’-HO-&H, 4’sHO-CGH, C,H, 4’.HO-C,H, 0.36 
6c 4’.HO-&H, 4’sHO-CsH, C,H, 4’.HO-&H, 0.62 
6d 4’-HO-C,H, 4’sHO-CGH, C,H, 4’-HO-C,H, 0.1 7 
12 Q-‘s 4’sHO-CsH, C,H, 4’-HO-C,H, 0.25 
17 4’.HO-C,H, ‘2% 4’-HO-&H, C,H, 0.37 
RBA, relative binding affinity (estradiol = 100%). 
Table 3 Figure 9 
Estrogen receptor binding data for thiazoles 22a, 22b and 
oxaroles 29 and 81. 
R2 
Compound 
22a 
22b 
29 
31 
HO 
X R’ R2 RBA 
S 4’-HO-CsH, H 0.018 
S 4’-HO-C,H, W, 0.041 
0 4’-HO-C&H, C&h <O.OOl 
0 W, 4’-HO-C,H, 0.027 
increases with substituent size up to a point, are well known 
both in steroidal systems (lip- and 16a-substituents) [36] 
and in other non-steroidal ligand series (such as Z-phenylin- 
doles [37], tetrahydrochrysenes [38] and so on), and proba- 
bly represent the filling of preformed pockets of limited 
volume in the receptor by these substituents [37]. The 
principal difference in binding, however, is between the 
tetra-substituted imidazoles (6b-d, 12 and 17) and the di- or 
tri-substituted imidazole (3 and 6a), the tetra-substituted 
ones having much higher affinity. There is little difference 
in binding between imidazoles 12 and 17, which have a 
different arrangement of nitrogen atoms in the heterocyclic 
core but display their four substituents in an identical 
fashion (Figure 9). The overall low binding affinity of the 
imidazoles as a class might be the result of the high inher- 
ent polarity of this heterocyclic system as compared with 
the pyrazoles, reflected by their higher chromatographic 
polarity in both normal and reversed phases systems. It is 
also of note that the dipole moment for imidazole is very 
Comparisons between ring pyrazoles (38b, 38d) and imidazoles (6b, 
12 and 17). 
large, 5.56 D [39], and this might be unfavorable for binding 
to the estrogen receptor. 
Table 4 
Estrogen receptor binding affinity data for pyrazoles and an 
isoxazole. 
N-X 
,~oH 
Compound X R R’ RBA 
35a N H H 0.009 
35b N Ws- H 0.020 
35c N C,H,CH2- H < 0.007 
35d N 4’-HO-C,H,- H 0.059 
38a N H V-6 0.015 
38b N Q-k WE 14.0 
38c N C,H&H,- CJ-43 0.150 
38d N 4’-HO-C,H,- C2H5 19.0 
41 0 - C2HS 0.006 
Table 3 shows the binding data for the two thiazoles and 
oxazoles. Although affinities are again very love, the more 
highly substituted thiazole again has the higher affinity 
(22a compared with 22b). The oxazole 29 has undetectable 
affinity for ER. The isomer 31, however, does have mea- 
surable, albeit low, binding. In contrast to imidazoles. thia- 
zoles and oxazoles do not have very high dipole moments 
[39]; so overall polarity is not likely to be the cause of their 
low ER binding affinity, although heteroatom orientation 
appears to play a role (29 compared with 31). In the imida- 
zole series, the compounds with the highest affinities were 
all tetra-substituted, however. As it is only possible to tri- 
substitute a thiazole or oxazole, this core structure might be 
unable to present sufficient peripheral substituents to afford 
ligands with good ER binding affinities. at least as far as we 
have investigated. 
The low binding affinities of the imidazoles, thiazoles and 
oxazoles are disappointing, although not surprising, con- 
sidering the relatively poor affinity of the most closely 
related benzothiazole reported by von Angerer [40] 
(Figure 1). The sparsely substituted monocyclic or poly- 
cyclic aromatic systems are also expected to be rather 
Research Paper Novel estrogen-receptor ligands Fink et al. 21 1 
HO OH 
12 (RBA 0.25) 
N-N 
38b (RBA 14) 
17 (RBA 0.37) I 
38d (RBA 19) 6b (RBA 0.38) 
Chemistry & Biology 
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Fiaure 10 Figure 11 
I 
-twofold 
increase 
;” 
H 
N-N’ 
,,yt-clOH 
38a 
(0.015) 
-threefold 
inCi%St! 
-1600-fold 
increase 
OH 
(0.028) 
-900.fold 
increase 
Chemq & Biology 
Comparison of the estrogen receptor binding affinity of four related 
pyrazoles with increasing substitution. 
N-N’ 
Ho&OH 
(0.009) 
II 
i Chemistry &Etiology 
Ab initio calculated conformations for 35a, 35b, 38a and 38b. 
and proper match between the peripheral substituents and 
several subsires on the receptor. and in the azole systems 
we have explored, it appears that this requires a tetra-sub- 
stituted ring (see below). Consistent with this is the low 
affinity of the isoxazole 41, whose affinitv is similar to the 
most closely related tri-substituted pyrazole 38a. 
planar. It is generally agreed that good ligands for the 
estrogen receptor need to have some degree of ‘thickness’ 
in the central portion of the l&and [38]. When alkyl sub- 
sticuents are added to either the imidazoles or thiazoles, 
their RBA increases (Tables $3). This increased binding 
could be due to an increase in steric bulk around the 
central portion of the molecule, the result, in part, of a 
twisting of some of the aromatic substituents (see below) 
or to an increase in lipophilicity. Regardless, the effects 
are not great, and in general the 1,3-azoles seem to present 
some special challenges that might best be investigated 
further by combinatorial approaches. 
Pyrazoles and isoxazoles 
The RBA data for the 1,2-azoles are presented in Table 4. 
Immediately apparent is the relatively high binding affin- 
ity of pyrazoles 38b and 38d. An interesting comparison can 
be made among compounds 35a, 35b, 38a and 38b 
(Figure 10). The disubstituted progenitor 35a has very low 
affinity; addition of a third subscituent, I-phenyl in 35b or 
4-ethyl in 38a, causes only a twofold or threefold increase 
in binding affinity, respectively. By contrast, addition of 
the fourth substituent (to give 38b) causes either an 900- or 
500-fold increase in binding affinity, respectively. ClearI!;, 
this is not additive behavior---two groups that each alone 
raise binding affinity twofold and threefold, together raise 
binding not sixfold but 1600-fold. This suggests that to 
achieve high binding affinity there needs to be a detailed 
There are other interesting trends in the pyazole series: 
replacement of the N-phenyl substituent (38b) with an 
N-benzyl group (38~) causes a dramatic lOO-fold reduction 
in binding. Both of these compounds are tctra-substituted 
pyrazoles. and they contain the homobibenzyl motif A that 
was considered to be an important factor for receptor 
binding (as do all of the other compounds in ‘l’able 1). 
The decrease in binding affinity in 38b compared with 38~ 
again suggests the need for a detailed match between 
ligand substituents and receptor subsites: the extra ‘kink’ 
in the benzyl substituent in 3812 might be repositioning 
the peripheral substituents in a less favorable geometry. 
The addition of a hydroxyl group at the pnra position of 
the N-phenyl substituent (compound 38d compared with 
38b) causes a minor increase in binding, indicating that 
polarity is well tolerated in this region of the receptor. 
Structural comparisons between high-affinity pyrazole 
ligands and other nonsteroidal ligands 
The conformation of pyrazoles 35a,b and 38a,b was deter- 
mined by & initio calculations at rhe 3-GZl* level 
(Figure 11). The action of A-strain is evident in these 
structures: even in the disubstituted system 35a, the 
.5-phenyl group is twisted -hO” out of the plane; this twist- 
ing increases as the t-hird (35b, 38a) and fourth (38b) sub- 
stituents are added to the pyrdzOk ring, so that in 38b the 
.5-phenyl substituent is nearly perpendicular to the pyra- 
zole core. In this conformation 38b resembles the genera1 
propeller-type conformation of the triar>ilethylene non- 
steroidal estrogens such as tamoxifen [41]. 
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Although the comparison of the conformations of tamoxifen 
with pyrazole 38b might give some idea of the reason 38b 
binds to ER with high affinity, it does not adequately 
explain why 35a, 35b and 38a have so much lower binding 
affinities. When the latter three pyrazoles are compared 
with 38b, it is apparent that there is little difference in 
conformation that could account for the large discrepancy 
in binding within the series. The reasons for the marked 
changes in RBA in response to very small changes in struc- 
ture, noted especially for the pyrazole series, are therefore 
not intuitively obvious from an examination of the structure 
of the hgands alone, although they are not entirely unex- 
pected on the basis of the behavior of other nonsteroidal 
ligands and the detailed fit of these congeners in the ligand- 
binding pocket of the estrogen receptor (see below). 
Analysis of the X-ray structure of the estrogen-receptor 
ligand-binding domain complexed with estradiol and the 
nonsteroidal ligand raloxifene 
The explanation that was previously proposed -that high- 
affinity binding to ER derives from a proper match between 
the peripheral substituents on the ligand and their comple- 
mentary binding regions on the receptor--can now be 
considered in some detail, because, recently, the X-ray 
structures of the estrogen receptor-a bound to cstradiol and 
the nonsteroidal ligand raloxifene have been reported [42]. 
The ligand-binding pocket in the ER-estradiol structure 
has a volume of approximately 450 A3, which is -200 Ai 
larger than the volume of estradiol [43] (Figure 1Za). As a 
result, there is a large hydrophobic space around the central 
portion of the binding pocket, especially in the regions 
corresponding to the 11 p position and, to a lesser degree, 
7a position (Figure 12a), which is consistent with the tol- 
erance that ER shows for binding steroids with large 
substituents at these positions [36]. A view of the ER- 
raloxifene structure is shown in Figure 12b. The core of 
this ligand is oriented in the same manner as estradiol and 
occupies much of the same space in the binding pocket, 
but the benzoyl substituent projects outward, askew of the 
ligand core, with the piperidinyl sidechain extending into 
an upper hydrophobic region, which is much more open 
due to the displacement of helix 12 [42]. 
Comparison between raloxifene and the tetra-substituted 
pyrazole Wb) 
The structure of the high-affinity pyrazole (38b) can be 
overlayed onto the structure of raloxifene (Figure 13a). In 
such a superposition, it is evident that the centroids of all 
three aromatic rings lie quite close to one another. This 
structural alignment can be used to place the pyrazole 38b 
into the l&and-binding pocket of the ER-raloxifene struc- 
ture (Figure 13b). With a minimal, energetically reasonable 
rearrangement of nearby residues (see Figure 13 legend), 
this ligand can fit quite comfortably in the raloxifene pocket 
(compare Figure 13b with Figure 12b). 
Figure 12 
Ligand binding pockets for (a) estradiol and (b) raloxifene. Structures 
were prepared from the crystallographic coordinates [431 by generating 
a solvent-accessible surface for the protein (green-blue dot surface) 
and for the ligand (purple). 
In the arrangement shown in Figure 13b, the two hydroxyl 
groups are positioned in such a manner that they could 
engage the same protein hydrogen-bonding partners as 
do the corresponding hydroxyl groups in raloxifene; the 
3-(p-hydroxyphenyl) substituent of 38b is mimicking the 
estradiol A-ring surrogate of raloxifene (i.e. the fused 
phenol of the benzothiophene unit) and the .5-Q-hydroxy- 
phenyl) group of 38b is mimicking the pendant p-hydroxy- 
phenyl group at position 2 of the benzochiophene (compare 
with Figure 1Zb). The 1-phenyl group of 38b overlies the 
benzoyl arene of raloxifene and projects into channel that 
exists in roughly the 1 lb direction in the ER-raloxifene 
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Figure 13 
(a) Overlay of pyrazole 3Sb with raloxifene and (b) pyrazole 38b in the 
binding pocket of the ER-raloxifene structure. (a) The overlay of the two 
ligands was obtained b a least-squares multifitting seven atoms in each 
molecule (rms=O.924 1. ): In each of the three benzene rings, the two 
atoms selected were the ones at the site of attachment and the ones para 
to this site; in addition, the phydroxy group on the 5phenyl substituent in 
pyrazole 38b was overlaid with the benzothiophene hydroxyl group. 
(b) Pyrazole 38b was pre-positioned into the ER-raloxifene crystal 
structure [42] from the overlay shown in (a). From this structure additional 
docking studies using flexiDock (Tripes, St Louis, MO) followed by a 
three-step minimization using the TRIPOS Forcefield were conducted to 
afford the final model (see the Materials and methods section). This 
minimization caused only small changes in the protein and ligand, but 
reduced the ligand-protein interaction energy to a reasonable level. 
structure. The 4-ethyl substituent on pyrazole 38b projects 
outwards from the heterocycle from a position that corre- 
sponds roughly to the sulfur atom of the benzothiophene 
ring system, and extends into an open pocket in the EK. 
When analyzed in this manner, one can appreciate that 
the pyrazole core can display these four substituents in a 
manner congruent with the same regions in the binding 
pocket of the estrogen receptor that accommodate corre- 
sponding portions of raloxifene. In addition, the high 
cost in binding affinity that results from the absence of 
either the I-phenyl or the 4-ethyl substituent (compare 
with Figure 10) suggests that proper registration of each 
of the four peripheral substituents into its appropriate 
binding subsite is supported by the interaction of the 
other three. By this analysis, it is therefore not surprising 
that all of the other heterocyclic systems that were only 
di-substituted or cri-substituted were low affinity ligands, 
at least with the substituents we have thus far investi- 
gated. The low-affinity of the tetra-substituted imidazoles, 
however, most likely derives from their high polarity, as 
noted (see below). 
The importance of core structural element in ligand 
binding: passive or active? 
The question raised initially-does the core scaffold in 
these novel ER ligands play only a passive role in their 
binding, merely displaying the peripheral substituents in 
an appropriate topology, or is its role more active or func- 
tional?-can be answered reasonably definitively from 
the results we have obtained so far. Clearly, with the sub- 
stituents we have examined, high-affinity binding was 
obtained only with those azoles that afforded the possi- 
bility of tetra-substitution. But of these, the 1,2-diazoles 
(pyrazoles) and the 1,Sdiazoles (imidazoles), only the pyra- 
zoles gave good binding. Although there are not many 
direct comparisons that can be made between these two 
diazole systems, pyrazole 38b and imidazoles 12 and 17 are, 
in fact, just ring nitrogen isomers of one another, having 
otherwise identical peripheral groups and functionality 
(Figure 9). The same is true for pyrazole 38d and imidazole 
6b. In both cases, however, the pyrazole partner binds to 
ER with -30-36fold higher affinity than the isomeric 
imidazole(s). This would suggest that the core structure 
does play more than a passive role in ER binding, although, 
as noted before, the high polarity and significant dipole 
moment of the imidazole might be the principal reason for 
the difference in this case. The issue of the functional role 
of the core scaffold in ER binding needs to be investigated 
further in these and other heterocyclic systems. 
Significance 
Compounds with a remarkable variety of structures bind 
with high affinity to the estrogen receptor (ER), and 
many nonsteroidal ligands have been prepared in the 
search for agents that have improved tissue-selectivity 
profiles. The application of combinatorial approaches to 
the development of selective ER ligands, however, is still 
in a state of infancy. 
Based on a simple pharmacophore model consisting of a 
core scaffold and various peripheral groups we have 
designed systems that display the peripheral groups on 
simple heterocyctic core systems, which are readily pre- 
pared by simple condensation reactions. Here, we describe 
the synthesis and ER-binding affmity of various substi- 
tuted 1,2- and 1,3-azoles. 
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No significant binding was found for members of the imi- 
dazole, thiazole or isoxazole classes, and this is rational- 
ized either by the inherent polarity of these compounds 
(imidazoles) or by their inability to carry a sufficient 
number of the types of peripheral substituents we have 
explored so far (thiazoles, oxazoles and isoxazoles). 
Several members of the pyrazole class did show good 
binding affinity, however, the best being a tetra-substi- 
tuted pyrazole 38d. Both 3% and 38d bear an unexpect- 
edly close conformational relationship to the nonsteroidal 
ligand raloxifene. 
Compounds such as 38b and 38d are well suited to com- 
binatorial synthesis using solid-phase methods. The large 
differences in binding affinity that result from small 
structural changes suggest that a thorough investigation 
of many possible combinations of core structures and 
peripheral substituents will be needed to identify novel 
high-affinity ligands for the ER that can be evaluated for 
their selective biological activity. The solid-phase combi- 
natorial synthesis of pyrazole libraries is currently 
underway and has yielded other high-affinity ligands for 
the estrogen receptor (S.R.S. and J.A.K., unpublished 
observations). Some of these heterocycles have also 
shown intriguing biological activity [431. 
Materials and methods 
General methods 
All reactions using water- or air-sensitive reagents were conducted 
under an Ar atmosphere with dry solvents. Solvents were distilled under 
N, as follows: CH,CI, from CaH,, tetrahydrofuran (THF) from sodium 
benzophenone ketyl, dimethylformamide (DMF) from MgSO,, and 
hexanes from CaSO,. Triethylamine was distilled over CaH,. All other 
reagents were purchased from commercial suppliers and used without 
further purification. Reactions were all monitored using thin-layer chro- 
matography (TLC), performed on 0.25 mm silica gel glass plates con- 
taining F-254 indicator. Visualization on TLC was achieved by UV light 
(254 nm), iodine vapors, or phosphomolybdic acid indicator. Flash 
chromatography was performed using Woelm 32-63pm silica gel 
packing unless otherwise noted. 
‘H NMR and i3C NMR spectra were recorded on a Varian U400, 
Varian U500 or Varian INOVA 750. NMR spectra chemical shifts (6) 
are reported in parts per million downfield from TMS and referenced 
with either TMS internal standard for CDCI,, acetone-d,, MeOD-d,, or 
DMSO-d, solvent peak. NMR coupling constants are reported in 
Hertz. Electron ionization (El) spectra were obtained using a Finnigan-- 
MATCH5 spectrometer at 70 eV. Fast atom bombardment (FAB) were 
recorded on a VG ZAB-SE spectrometer. High-pressure liquid chro- 
matography (HPLC) was performed on a SpectraPhysics PlOO 
solvent delivery system with ultraviolet detection at 254 nm. Elemental 
analysis was performed by the Microanalytical Service Laboratory at 
the University of Illinois. All characterized compounds are chromato- 
graphically homogeneous. 
Relative binding affinities 
Assays were performed as reported previously [44] using lamb uterine 
cytosol diluted to approximately 1.5 nM of receptor, which was incu- 
bated with buffer of several concentrations of unlabeled competitor 
together with 10 nM [sHIestradio for 18-24 h. Free ligand was removed 
by adsorption onto dextran-coated charcoal. Unlabeled competitors were 
prepared in 1 :l DMF:TEA to ensure solubility. 
Molecular modeling and docking studies 
Solvent-accessible surfaces were generated (Figures 12 and 13) using 
the QCPE Connolly Program module (Indiana University) in Sybyl 6.5 
(Tripes, St. Louis, MO). Figure 13b: the pre-positioned pyrazole 38b was 
used for additional docking studies using the Tripos FlexiDock module. 
Both hydrogen-bond donors and acceptors within the pocket surround- 
ing the ligand and the ligand itself in addition to select rotable torsional 
bonds were defined in order to afford an optimal docked-structure prior 
to molecular mechanics minimization. With the protein backbone held 
rigid, the ligand and the protein residues within 8A of the ligand were 
then minimized using a step-wise approach: first torsional bonds about 
the ligand were minimized holding the receptor fixed, followed by mini- 
mization of the receptor holding the ligand fixed, and then minimization of 
both the ligand and receptor. Minimizations were done using the TRIPOS 
Forcefield (as implemented in the program Sybyl) with the Powell gradi- 
ent method and default settings (final RMS < 0.05 kcal/mol-A). 
Representative chemical synthesis 
4,5-Dif4-methoxypheny/)-1H-imidazo/e (2). To 4,4’-dimethoxybenzil (1) 
(2.0 g, 7.4 mmol) and p-formaldehyde (1 .O g, 1 1 .l mmol) was added for- 
mamide (50 ml). The bright yellow suspension was heated to reflux 
(220°C) for 2 h. The reaction mixture was then cooled to room tempera- 
ture then to 0°C. The crystals that formed were filtered and recrystallized 
from EtOAc to afford 2 (2.4 g, 86%). mp 183-184°C (lit [16] mp 
183-184°C); ‘H NMR (400 MHz, MeOH-d,) 6 7.64 (s, lH), 7.44 (d, 
4H, J= 7.50), 6.89 (d, 4H, J= 7.50), 3.79 (s, 6H); 13C NMR (100 MHz, 
MeOH-d,) F 158.4, 135.2, 129.1, 128.9, 122.6, 114.2, 55.3. 
General demefhylafion procedure using BBr,. To a stirring solution of 
the methyl-protected heterocycle (1 equiv) in CH,CI, at -78°C was 
added a solution of BBr, (4-5 equiv) as a 1 N solution in CH,CI,. The 
reaction were allowed to warm to room temperature and stirred for 18 h. 
After quenching with H,O, the layers were separated and the aqueous 
layer extracted with EtOAc (3 x 5 ml). The combined organic layers 
were dried over Na$O,, fitered and concentrated to afforded the crude 
phenols. Flash chromatography afforded the demethylated products. 
4,5-Di(4-hydroxyphenyfl-IH-imidazole (3). lmidazole 2 (100 mg, 0.35 mmol) 
afforded 3 (52 mg, 59%) by the general BBr, demethylation proce- 
dure. 1H NMR (400 MHz, CDCI,) 6 14.56 (br s, lH), 9.93 (br s, lH), 
9.24 (s, lH), 7.24 (d, 4H, J=8.47), 6.82 (d, 4H, l=8.40); MS (FAB) 
m/z (relative intensity, Yo) 253.1 (MH+ 24), 169.2 (100). 
2,4,5-Tri(4-mefhoxyphenyl)-IH-imidazole (4). A suspension of 4,4’-di- 
methoxybenzil (1) (4.0 g, 15 mmol) and p-anisaldehyde (20 ml, 164 mmol) 
and formamide (100 ml) was heated to reflux (220°C) for 2 h, during 
which time the reaction mixture became homogeneous. The reaction was 
then cooled to 0°C and the precipitated product 4 was filtered. The light 
yellow powder was recrystallized from MeOH/H,O to afford 3.80 g of 4 
[19] (66%). mp 89-91% (lit [19] mp 88-94%). ‘H NMR (400 MHZ, 
Acetone-d,) 6 7.98 (d, 2H, J= 8.88), 7.42 (d, 4H, J= 8.52), 7.01 (d, 2H, 
J=8.83), 6.92 (brs, 4H), 3.79 (s, 3H), 3.75 (s, 6H); 13C NMR 
(1OOMHz Acetone-d,) 6 162.4, 159.9, 158.9, 145.4, 131.0, 129.0, 
128.9, 12’6.6, 132.8, 114.0, 113.7, 113.6; MS (El, 70eV) m/z (relative 
intensity, Yo) 386.2 (M+, loo), 371 (30), 280 (loo), 265 (30); HRMS 
calc’d for C,, H,,N,O,: 345.123800, found: 345.123918. 
General N-alkylation procedure for imidazoles. A solution of imidazole 4 
(200 mg, 0.52 mmol) in THF (10 ml) and DMF (1.5 ml) was cooled to 
5°C. NaH (31 mg, 0.78 mmol) was added as 60% dispersion in mineral 
oil. The reaction mixture was warmed to room temperature for 1 h and 
respective alkyl halide (0.04 ml, 0.62 mmol) was added. The resulting 
suspension was heated to reflux for 12 h, then cooled to room tempera- 
ture. The light precipitate was filtered, and the filtrate was concentrated 
under vacuum to a yellow solid which was flashed on silica (30% 
EtOAc/Hexanes) to afford alkylated products 5b-d in 80-90% yields. 
1-Ethy/-2,4,5-tri(4-methoxypheny/j-imidazole (56). ‘H NMR (400 MHz, 
CDCI,) 6 7.60 (AA’XX’, 2H, J,x=8.88, J,= 2.51), 7.46 (AA’XX’, 2H, 
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J,,=8.97, J/,*=2.56), 7.32 (AA’XX’, 2H, J,,=8.88, J,,,=2.56),7.00 
(AA’XX’, 2H, J,,=8.88, J,=2.51), 6.99 (AA’XX’, 2H, J,,=8.88, 
JAA= 2.56), 6.74 (AA’XX’, 2H, J,,=0.97, J,=2.56), 3.87 (q, 2H, 
J=7.32), 3.87 (s, 3H), 3.85 (s, 3H), 1.00 (t, 3H, J= 7.14); 13C NMR 
(lOOMHz,CDCI,) 6 160.0, 159.7, 158.1, 146.8, 137.2, 132.4, 130.5, 
127.9, 127.5, 123.8, 123.7, 114.5, 114.0, 113.5, 55.3, 55.2, 55.1, 
39.5, 16.2. 
2,4,5-Tri(4-hydroxypheny/)-IH-imidazole f6a). According to the general 
B&s demethylation procedure above, imidazole 4 (3.0 g, 7.8 mmol) 
afforded 6a as a green-orange solid that darkened upon exposure to air 
(1.8 g, 68%). mp 203-205°C; ‘H NMR (400 MHz, Acetone-d,) 6 7.93 
(AA’XX’, 2H, J,,=8.97, J,=2.47), 7.40 (AA’XX’, 4H, J,,=8.60, 
J,=2.47), 6.89 (AA’XX’, 2H, J,,=8.97, J,,=2.47), 6.80 (AA’XX’, 
2H, Jnx = 8.60, JM= 2.47); r3C NMR (100 MHz, Acetone-de) 6 157.9, 
156.4, 145.9, 129.0, 126.8, 124.0, 123.4, 121.3, 115.0, 114.7; MS 
(FAB) m/z (relative intensity, Yo) 345.1 (M+H+, 1 Of, 353 (1 O), 169 (100); 
HRMS calc’d for C2,H,eN203: 345.123800, found: 345.123918. 
7 -ffhy/-2,4,5-trii(4-hydroxypheny/)-imidazole (6L$. According to the 
general BBr, demethylation procedure above, imidazole 5b (185 mg, 
0.46 mmol) afforded 5b (107 mg, 62%). mp 150-153’C; ‘H NMR 
(400 MHz, Acetone-d,) 6 7.51 (AA’XX’, 2H, J,,=8.52, Jnn= 2.42), 
7.34 (AA’XX’, 2H, J,,,=8.71, J,,=2.39), 7.24 (AA‘XX’, 2H, 
J,=8.63, J,=2.41), 6.97 (AA’XX’, 2H, J,=8.58. J,=2.31), 6.90 
(AA’XX’, 2H, J,=8.75, JM= 2.31), 6.64 (AA’XX’. 2H, J,x=8.96, 
J,=2.43), 3.93 (q, 2H, J=7.19), 0.98 (t, 3H, J=7.12); ‘% NMR 
(100 MHz, Acetone-d,) 6 158.2, 157.9. 155.9, 146.5, 136.8, 132.5, 
130.3, 127.9, 127.8, 126.6, 122.5, 122.4, 116.0, 115.4, 114.8, 17.9, 
15.4; MS (FAB) m/z (relative intensity, %) 372.1 (MH+, 100) 343 (15), 
275 (lo), 214 (251, 162 (301, 148 (30); HRMS calc’d for 
C,,H,,N,O,: 372.147251, found: 372.147393. 
I-Ethyl-2,5-(4-methoxypheny&4-phenyl imidazole (I 7). Azido-ketone 
9 (50.0 mg, 0.187 mmol) and imine 10 (92.0 mg, 0.564 mmol) were 
dissolved in THF (15 ml). EtsN (29.0 yh, 0.208 mmol) was added via 
syringe and reaction stirred at room temperature for 48 h. The reac- 
tion mixture was then poured into H,O and extracted with CH,CI,, 
organic fractions were pooled, dried over Na,SO,, filtered and solvent 
removed under reduced pressure. The intermediate, 2,5-dihydro- 
2-hydroxyimidazole, used in next step without further purification or 
characterization, was taken up CH,CI, (10 ml). Solution was cooled 
to 0°C and TFA (14.4 pl, 0.187 mmol) was added via syringe. Reac- 
tion stirred at 0°C for 36 h. The mixture was diluted with CH,CI, 
(10 ml) and washed with H,O, sat. NaHCO,, and sat. NaCl succes- 
sively. The organic fraction was dried over Na,SO,, flltered and solvent 
removed under reduced pressure. Purification by flash column chro- 
matography (1:2 EtOAc:Hexanes) and recrystallization from CH,CI,/ 
Hexanes afforded imidazole 11 as a white solid (24.6 mg, 340/, yield 
from azide 9). ‘H NMR (500 MHz, CDCI,) 6 7.63 (AA’XX’, 2H, JAx= 
8.81, JXr = 2.53), 7.54 (m, 2H), 7.34 (AA’XX’, 2H, J,,= 8.80, JXK= 
2.45), 7.20 (m, 2H), 7.12 (m, IH), 7.02 (AA’XX’, 2H, J,,=8.78, JAA 
= 2.54), 7.01 (AA’XX’, 2H, JAx=6.43, J&,.=2.57), 3.90 (q, 2H, 
J=7.08), 3.89 (s, 3H), 3.87 (s, 3H), 1.02 (t, 3H, J=7.17); 13C NMR 
(125 MHz, CDCI,) S 200..8, 160.0, 159.8, 147.0, 134~8, 132.3 (2), 
130.5 (2) 129.3, 128.9, 128.0 (2) 126.6 (2), 126.0, 123.6, 114.5 
(2), 114.0 (2), 55.33, 55.28, 36.4, 16.2; MS (El, 70eV) m/z 384.2 
(M+); Anal. calc’d for C,,H,,N,O1, C: 78.10%, H: 6.29%, N: 7.29%, 
found, C: 77.910/o, H:6.28%, N: 7.28%. 
Genera/ demethylatjon procedure using BFs*SMe,. To a stirring solu- 
tion of the methyl protected heterocycle (1 equiv) in CH,CI, (8 ml) at 
room temperature was added BF,*SMe, complex (75 equiv). After stir- 
ring for 24 h, solvent and excess reagent were evaporated under nitro- 
gen stream in hood. Residue was taken up in EtOAc and washed with 
Hz0 and sat. NaCI. Organic extract was dried over Na$O,, filtered 
and solvent removed under reduced pressure. The resulting residue 
was purified though a silica plug, eluting with EtOAc. Solvent evapora- 
tion afforded the deprotected products. 
1 -Efhyl-2,5-(4-hydroxypheny/)+phenyl imidazole (12). lmidazole 11 
(12.0 mg, 0.031 mmol) was demethylated according to the general 
BF,*SMe, procedure to afford imidazole 12 as an off-white powder 
(10.6 mg, 95%). ‘H NMR (500 MHz. Acetone-de) 6 7.80 (AA’XX’, 2H, 
J,=8.81, Jxx,=2.44), 7.47-7.49 (m, 2H), 7.44 (AA’XX’, 2H, J,,=8.65, 
J,,=2.44), 7.37-7.40 (m, 3H), 7.14 (AA’XX’, 2H, J,,=8.80, J,,=2.43), 
7.06 (AA’XX’, 2H, J,,=8.68, J,.=2.46), 4.25 (q, 2H, J=7.28), 1.17 
(t, 3H, J=7.29); MS (FAB) m/z 357.2 (M+H+); HRMS calc’d for 
C,,H,,N,O,: 357.160303, found: 357.160000. 
5-Ethyl-1,4-(4.methoxyphenylj-2-phenyl imidazole (16). Keto-amide 15 
(110.0 mg, 0.273 mmol) and ammonium acetate (105.0 mg, 1.362 mmol) 
were heated to reflux in acetic acid (10 ml) for 48 h. Acetrc acid was 
removed under reduced pressure, resulting residue was taken up in 
EtOAc, washed with sat. NaHCO,, H,O, and sat. NaCI. Organic extracts 
were dried over Na,SO,, filtered and solvent removed. Product was 
purified by ftash column chromatography (1:4 EtOAc:Hexanes) and 
recrystallization from CH,CI,/Hexanes to grve imidazole 16 as a white 
solid (25.7 mg, 25%). ‘H NMR (500 MHz, CDCI,) 6 7.72 (AA’XX’, 2H, 
J,,=8.29, J,,,=2.55), 7.14 (m, 2H), 7.21 (m, 3H), 7.19 (AA’XX’, 2H, 
J,=9.33, Jxx=2.71), 6.98 (AA’XX’, 2H, J,,=8.48, J,,=2.52), 6.96 
(AA’XX’, 2H, I,, =8.62, J,,.=2.74), 3.87 (s, 3H), 3.85 (s, 3H), 2.67 
(q, 2H, J=7.48), 1.01 (t, 3H, J= 7.45); MS (El, 70 eV) m/z 384.2 (M+). 
5-Ethyl-1,4-(4-hydroxyphenyl)-2phenyl imidazole (17). lmidazole 16 
(25.0 mg, 0.065 mmol) was demethylated as outlined in general BFaSMe, 
procedure above to give deprotected imidazole 17 as an off-white 
powder (20.2 mg, 87%). ‘H NMR (400 MHz, Acetone-d,) S 9.04 (br s, 
lH), 8.51 (br s, lH), 7.64 (AA’XX’, 2H, J,,=8.73. Jxx= 2.51), 7.50. 
7.47 (m, 2H), 7.31-7.27 (m, 5H), 7.01 (AA’XX’, 2H, J,,=8.94, 
J,.=2.76). 6.94 (AA’XX’, 2H, J,,=8.73, JM,=2.52), 2.69 (q< 2H, 
J = 7.48), 1.02 (1, 3H, J = 7.49); MS (FAB) m/z 357.1 (M+H+); HRMS 
calc’d. for r&H,, N,O,: 357.1603, found 357.1602. 
2,4-Di(4-methoxyphenyl)-thlazole f27a). A suspension of thioamide 19 
(1.3 g, 7.9 mmol) and cr-bromo-4’.methoxy-acetophenone (20) (1.8 g, 
7.9 mmol) in DMF (10 ml) was heated to reflux for 1 h, until it became 
homogeneous. The heat was removed and the reaction was stirred for 
15 h at room temperature. The reaction mixture was poured into Hz0 
(50ml) and the solid precipitate was filtered to afford crude 21a. 
Recrystallization from CHaNO, afforded pure 21a as light yellow crys- 
tals (1.8 g, 81%). ‘H NMR (400 MHz, CDCI,) 6 7.98 (AA’XX’, 2H, 
J,=8.87, J,,= 2.53), 7.63 (AA’XX’. 2H, J,,=8.94, JAA= 2.48), 6.86 
(AA’XX’, 2H, J,,=8.87, J,=2.53), 6.85 (AA’XX’, 2H, J,,=8.94, 
J,=2.48), 7.26 (s, lH), 3.86 (s. 3H), 3.85 (s, 3H); 13C NMR 
(400 MHz, CDCt,) 6 167.5, 160.9, 159.4, 155.6, 127.9, 127.6, 127.4, 
126.6, 114.1, 113.9, 109.9, 55.3, 55.2; MS (El, 70 eV) m/z (relative 
intensify, Yo) 297.1 (M+, IOO), 282.1 (lo), 164.1 (30), 149.1 (55), 133.1 
(10). 121.1 (25), 77.1 (15); HRMS calc’d for C,,H,,NSO,: 297.082469, 
found: 297.082351. 
2,4-Di(4-hydroxyphenyl)-thiazole (22a). Thiazole 21a (1 .O g, 3.6 mmol) 
was demethytated using BBr, as outlined in the general procedure 
above to afford 22a (430 mg, 45%). mp 218-221°C; ‘H NMR 
(400 MHz, Acetone-de) 6 8.84 (br s, 2H), 7.92 (AA’XX’, 4H, JAx = 8.57, 
J,=2.17), 7.58 (s, lH), 6.96 (AA’XX’, 2H, J,,=8.79, J,=2.51), 
6.92 (AA’XX’, 2H, J,,=8.78, JM= 2.44); ‘% NMR (100 MHz, 
Acetone-de) 6 168.2, 159.3, 157.2, 155.8, 127.7, 127.3, 126.2, 
125.1, 115.2, 114.9, 109.3; MS (El, 70 eV) m/z (relative intensity, o/o) 
296.1 (M+, loo), 150.1 (27) 121.1 (1 l), 78.1 (8); HRMS catc’d for 
C,,H, ,NSC,: 269.051163, found: 269.051051. 
2,4-(4-Methoxyphenyl)-5-phenyl oxazoie (28). Azido-ketone 27 (0.18 g, 
0.673 mmol) and p-anisaldehyde (0.25 ml, 2.05 mmol) were dissolved 
in THF (15 ml). Et,N (94.0 11, 0.674 mmol) was added via syringe and 
reaction stirred at room temperature for 48 h. The reaction mixture was 
then poured into H,O and extracted with CH,CI,, organic fraction was 
dried over Na,SO,, filtered and solvent removed under reduced pres- 
sure. Resultrng intermediate 2,5-dihydro-5-hydroxyoxazole, used in next 
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step without further purification or characterization, was taken up 
CH,CI, (10 ml). Solution was cooled to O’C and TFA (54.0 ~1, 
0.701 mmol) was added via syringe. Reaction stirred at 0°C for 36 h. 
The mixture was diluted with CH,CI, (10 ml) and washed with H,O, 
sat. NaHCO,, and sat. NaCl successively. Organic extracts were com- 
bined, dried over Na,SO,, filtered and solvent removed under reduced 
pressure. Purification by flash column chromatography (1:2 EtOAc: 
hexanes) and recrystallization from CH,CI,/Hexanes afforded oxazole 
28 as a white solid (72.4 mg, 30% yield from azide 27). mp 125- 
128% (lit. 1271 mp 126-l 27Y); tH NMR (500 MHz, CDCI,) 6 7.84 
(AAXX’, 2H, J,,=8.89, JXx,= 2.47), 7.43 (AAXX’, 2H, Jnx= 8.83, 
J,,.=2.48), 7.53 (m, 2H), 7.32 (m, 2H), 7.26 (tt, lH, J= 7.03, 1.42), 
6.97 (AA’XX’, 2H, J,,=8.85, Jti=2.53), 6.88 (AA’XX’, 2H, J,,=8.70, 
JAA.= 2.53), 3.84 (s, 3H), 3.81 (s, 3H). 
2,4-(4.Hydroxyphenyl)dphenyl oxazole (29). Oxazole 28 (22.0 mg, 
0.062 mmol) was demethylated according to the general BFsSMe, 
procedure above to give deprotected oxazole 29 as an off-white 
powder (18.8 mg, 93%). ‘H NMR (500 MHz, Acetone-d,) 6 9.43 (br s, 
lH), 8.90 (br s, lH), 8.08 (AA’XX’, 2H, J,,=9.06, J,,.=2.62), 7.61 
(m, 2H), 7.49 (m, 3H), 7.44 (AA’XX’, 2H, J,,=8.97, J,,.= 2.44), 7.12 
(AA’XX’, 2H, J,,=8.87, J,,=2.50), 6.95 (AA’XX’, 2H, J,,=8.86, 
J,,=2.42); MS m/z 329.1 (M+); HRMS calc’d. for C,,H,,NO,: 
329.1052. found 329.1285. 
2,5-(4-Methoxyphenyl)+phenyl oxazole (30). A solution of bromo- 
ketone 26 (87.0 mg, 0.285 mmol) and p-methoxybenzamide (43.0 mg, 
0.285 mmol) in toluene was heated to reflux for 36 h. Toluene was 
removed under reduced pressure and resulting residue purified by 
flash column chromatography (1:4 EtOAc:Hexanes). Recrystallization 
of desired product from CH,Cl,/hexanes afforded oxazole 30 as a col- 
orless solid (52.9 mg, 52%). mp 147-149%; ‘H NMR (500 MHz, 
CDCI,) 6 8.08 (AA’XX’, 2H, JAx= 8.58. J,,,=2.24), 7.72 (m, 2H), 7.59 
(AA%‘, 2H, J,,=8.72, J,,.=2.31), 7.39 (m, 2H), 7.33 (m, lH), 6.99 
(AA’XX’, 2H, J,,=8.63, J,,=2.26), 6.92 (AA’XX’, 2H, J,,=8.68, 
JAA>= 2.67). 3.88 (s, 3H), 3.85 (s, 3H); i3C NMR (100 MHz, CDCI,) F 
161.2, 159.9, 159.7, 145.1, 135.3, 132.9, 128.6 (2) 128.1 (2), 128.0 
(2), 127.96 (2), 127.9, 121.7. 120.3, 114.2 (2), 114.1 (2), 55.4, 55.3; 
MS m/z 357.2 (M+). 
2,5-(4-Hydroxyphenyti-4-phenyl oxazole (31). Oxazole 30 (22.0 mg, 
0.062 mmol) was demethylated according to the general BF,*SMe, 
procedure above to give deprotected oxazole 31 as an off-white 
powder (18.1 mg, 89%). ‘H NMR (500 MHz, Acetone-d,) 6 8.93 (br s, 
lH), 8.77 (br s, lH), 7.99 (AA’XX’, 2H, J,,=8.83, J,,.=2.41), 7.72 
(m, 2H), 7.53 (AA’XX’, 2H, J,,=8.77, J,,.= 2.46), 7.40 (m, 2H), 7.34 
(tt, lH, J=7.36, 1.33), 6.99 (AA/XX’, 2H, J,,=8.70, JAA’=2.40), 6.92 
(AA’XX’, 2H, J,,=8.83, JAA’= 2.46); MS m/z 329.1 (M+); HRMS 
calc’d for C,, H,,NO,: 329.1052, found 329.1055. 
Genera/ procedure for pyrazole synthesis. A suspension of diketone 
(1 equiv) and appropriate hydrazine hydrochloride (3-5 equiv) in a 3:l 
mixture DMF:THF was heated to reflux for 16-24 h with reaction progress 
being monitored by TLC for disappearance of starting material. The 
reaction mixtures was cooled to room temperature and poured into 
iced sat. LiCl solution (10 ml) and EtOAc (10 ml). The layers were sep- 
arated and the organic layer was washed with brine (10 ml), dried over 
MgSO,, filtered and concentrated. Purification using flash column 
chromatography (EtOAc/hexanes systems) afforded the pyrazoles. 
3,5-di(4-mefhoxypheny/]-7H-pyrazo/e (34a). Diketone 33 (91 mg, 
0.32 mmol) and hydrazine (0.1 ml, 3.2 mmol) were reacted as outlined 
in general pyrazole procedure to afford 34a [45] as an off-white solid 
(32.6 mg, 38%). mp 172-l 75% (lit [45] mp 174%); ‘H NMR (400 MHz, 
CDCI,) 6 7.73 (AA’XX’, 4H, Jnx= 8.73, JAA= 2.42), 6.97 (AAXX’, 4H, 
J,=8.73, J,=2.42), 6.80 (s, lH), 3.72 (s, 6H); ‘sC NMR (lOOMHz, 
CDCl3) 6 159.9, 148.3, 126.8, 123.0, 112.9, 98.6, 54.5; MS (FAB) 
m/z (relative intensity, ‘J/o) 281 (MH+, 100). 
1 -Phenyl-3,5-di(4-methoxyphenyti-pyrazole (346). Diketone 33 (100 mg, 
0.35 mmol) and phenyl hydrazine hydrochloride (500 mg, 3.5 mmol) were 
reacted as outlined in general pyrazole procedure above to afford 34b 
[46) (30 mg, 250/o). mp 159-161°C (lit [461 mp 163°C); rH NMR 
(400MHz, CDCI,) 6 7.82 (AA’XX’, 2H, J,=8.96, J,,=2.44), 7.24- 
7.20 (m, 5H), 7.20 (AA’XX’, 2H, J,,=8.79, J,=2.46), 6.99 (AA’XX’, 
2H, JAx=8.79, J,=2.46), 6.84 (AA’XX’, 2H, J,,=8.96, f,=2.44), 
6.70 (s, 1 H), 3.84 (s, 3H), 3.80 (s, 3H); i3C NMR (100 MHz, CDCI,) 6 
159.4, 151.5, 144.1, 140.0, 129.9, 128.8, 127.2, 126.9, 125.5, 125.2, 
122.9, 113.9, 1 13.8, 104.1, 55.2, 55.1; MS (El, 70 eV) m/z (relative 
intensity, O/o) 356 (M+, loo), 341 (19), 135 (89); HRMS calc’d for 
C23H20N202: 356.15241, found: 356.152478. 
3,5-Di(4-hydroxyphenyi)-1 H-pyrazole f’35a). Pyrazole 34a (20 mg, 
0.07 mmol) was demethylated with BBr, according to the general pro- 
cedure to afford 35a [47) as an off-white solid (11 mg, 63%). IH NMR 
(400 MHz, Acetone-d,) 6 8.58 (br s, 2H), 7.75 (AA’XX’, 4H, JAx = 8.95, 
J,=2.46), 6.93 (AA%‘, 4H, J,,=8.95, J,,=2.46), 6.83 (s, 1H); 13C 
NMR (100 MHz, Acetone-d,) 6 157.1, 148.3, 126.5, 123.0, 115.3, 97.5; 
MS (Cl, CH,) m/z (relative intensity, O/o) 253.1 (MH+, loo), 237(10), 
161 (5), 123 (15). 
1 -Phenyl-3,5-di(4-hydroxyphenyl)-pyrazole (35b). Pyrzuole 34b (20 mg, 
0.06 mmol) was demethylated with BBr, according to the general proce- 
dure to afford 34b [47) as an off-white solid (11.5 mg, 58%). ‘H NMR 
(400 MHz, CDCI,) 6 8.64 (s, lH), 8.45 (s, 1H) 7.79 (AA’XX’, 4H, 
J,,=8.78, J,=2.38), 7.36 (m, 5H), 7.14 (AAXX’, 4H, JAx = 8.60, 
JAA= 2.47), 6.90 (AA’XX’, 2H, J,,=8.78, J,=2.38), 6.81 (AA’XX’, 2H, 
J,,=8.78, JAA= 2.47), 6.80 (s, 1 H); ‘% NMR (100 MHz, CDCI,) 6 
157.5, 157.3, 151.3, 144.1, 140.6, 129.9, 128.6, 126.8, 126.7, 124.9, 
122.2, 122.1, 115.2, 115.1, 103.7; MS (El, 70 eV) m/z (relative intensity, 
O/o) 362.1 (M+, 85) 328.1 (100). 
4-fthy/-3,5-di(4-methoxyphenyl)-7 H-pyrazole (37a). Diketone 36 (100 mg, 
0.32 mmol) and hydrazine (0.12 ml, 3.2 mmol) were reacted as outlined 
in the general pyrazole procedure above to afford 37a as a while solid 
(69 mg, 7OYo). ‘H NMR (400 MHz, CDCI,) 6 7.50 (AA’XX’, 4H, 
J,,=8.84, J,=2.48), 6.94 (AA’XX: 4H, J,,=8.90, J,=2.50), 3.85 
(s, 3H), 2.71 (q, 2H, f=7.38), 1.07 (t, 3H, J=7.44); ‘3C NMR (100 
MHz, CDCI,) 6 159.4, 129.0, 127.4, 124.1, 116.8, 113.9, 55.1, 16.6, 
15.3; MS (El, 70 eV) m/z (relative intensity, O/o) 308.1 (M+, loo), 293.1 
(73) 160.1 (7) 134 (8). 
1 -Phenyl-4-ethyl-3,5-di(4-methoxyphenyl)-pyrazole (376). Diketone 36 
(100 mg, 0.35 mmol) and phenyl hydrazine hydrochloride (140 mg, 
0.96 mmol) were reacted as outlined in the general pyrazole procedure 
above to afford 37b as an orange solid (109 mg, 87%). ‘H NMR 
(400 MHz, CDCI,) 6 7.72 (AA’XX’, 2H, JAx= 9.03, JAA= 2.44), 7.24 (m, 
3H), 7.20 (m, 2H), 7.17 (AA’XX’, 2H, J,,=8.79, J,=2.44), 6.99 
(AA’XX’, 2H, J&x=8.79, J,=2.56), 6.90 (AA’XX’, 2H, J,,=8.79, 
J,=2.44), 3.86 (s, 3H), 3.83 (s, 3H), 2.63 (q, 2H, J=7.57), 1.04 (t, 
3H, J= 7.57); ‘% NMR (100 MHz, CDCI,) 6 159.6, 159.4, 150.8, 
141.2, 140.5, 131.5, 129.3, 128.8, 127.0, 126.7, 124.8, 123.5, 120.7, 
114.2, 114.1, 55.5, 55.4, 17.3, 15.8; MS (El, 70 eV) m/z (relative inten- 
sity, a/o) 356 (M+, loo), 341 (loo), 328 (15), 196 (25), 77 (40); HRMS 
calc’d for C,,H,,N,O,: 384.183582, found: 384.183778. 
4-Ethy/-3,5-di(4-hydroxyphenyu-I H-pyrazole f38aj. F’yrazole 37a (69 mg, 
0.22 mmol) was demethylated according to the general BBr, proce- 
dure to afford 38a as a white solid (35 mg, 57%). ‘H NMR (400 MHz, 
Acetone-d,) 6 7.49 (AA’XX’, 4H, JAx= 8.85, JAA = 2.46), 6.93 (AA’XX’, 
4H,J,,=8.64, J,=2.40), 2.73 (q, 2H, J=7.39), 1.07 (t, 3H, J=7.47); 
j3C NMR (100 MHz, Acetone-d,) F 156.9, 128.8, 124.3, 122.2, 1 15.4, 
115.2, 16.5, 14.9; MS (Cl, CH,) m/z (relative intensity, O/o) 282.1 
(M+H+, loo), 263.1 (1 O), 187.1 (20). 
7 -Phenyl-4-ethyl-3,5-di(4-hydroxypheny/)-pyrazoie f38b). Pyrazole 37b 
(100 mg, 0.26 mmol) was demethylated according to the general BBrs 
procedure to afford 38b as a white solid (50 mg, 54O/o). ‘H NMR 
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(400 MHz, MeOH-d,) 6 7.51 (AA’XX’, 4H, Jnx = 8.67, JAn= 2.47), 7.24- 
7.42 (m, 5H), 7.05 (AAXX’, 4H, J,=8.81, J,=2.40), 6.88 (AA’XX’, 
2H, J,=8.67, J,=2.46), 6.78 (AA’XX’, 2H, J,=8.81, J,=2.40), 
2.60 (q, 2H, J= 7.53), 0.98 (t, 3H, J= 7.39); MS (El, 70 eV) m/z (relative 
intensity, %) 356.1 (M+, loo), 341.1 (1001, 328.1 (15), 196.1 (251, 77 
(40); HRMS calc’d for C,,H,, N,O,: 357.161155, found: 357.160303. 
3,5-Di(4-methoxyphenyl)isoxazole (40). To a solution of oxime 39 
(1 .O g, 6 mmol) in THF (20 mL) at 0“C was added nBuLi (9.11 ml. 
13.3 mmol) as a solution in hexanes. The clear solution was stirred for 
30 min at O’C then methyl 4-methoxybenzoate (498 mg, 3 mmol) was 
added as a solution in THF (5 ml) over 5 min. The reaction mixture was 
stirred at 0°C for 30 min, then warmed to room temperature. 5 N HCI 
(10 ml) was added and the biphasic reaction mixture was brought to 
reflux overnight (12 h). Upon cooling to O’C, isoxazole 40 precipitated 
[331 and was collected via filtration (450 mg, 270/,). mp 174-I 77’C (lit 
1331 mp 176-l 77“C); ‘H NMR (400 MHz, Acetone-d,) 6 7.66 (AA’XX’, 
2H, J,=8.88, J,=2.44), 7.63 (AA‘XX’, 2H, J,,=9.1, JAA= 2.15), 
6.86 (AAXX’, 2H, Jnx = 8.88, JAA = 2.441, 6.85 (AA’XX’, 2H, Jnx = 9.1, 
J,=2.44), 6.57 (s, IH), 3.73 (s, 3H), 3.72 (s, 3H); 13C NMR (100 
MHz, Acetone-d,) 6 169.8, 162.3, 160.8, 160.7, 127.9, 127.1, 121.5, 
120.0, 114.1, 114.0, 95.7, 55.1, 55.0; MS (El, 70 eV) m/z (relative 
intensity, %) 281 .I (M+, 5), 150.1 (20), 135.1 (100). 
3,5-Di(4-hydroxyphenyf)koxazo/e (41). lsoxazole 40 (300 g, 1 .l mmol) 
was demethylated according to the general BBr, procedure to afford 41 
[34] as a white solid (152 mg, 56%). mp 267-269’C (lit 1341 mp 
255°C); ‘H NMR (400 MHz, Acetone-d,) 6 10.07 (s, 1 H), 9.91 (s, lH), 
7.90 (d, 4H, J=8.79), 7.21 (s, IH), 6.88 (4H, t, J=9.38); 13C NMR 
(lOOMHz, MeOH-d,) 6 170.3, 162.8, 159.1, 127.7, 126.9, 119.9, 
118.7, 116.3, 1 15.1, 95.3, 95.0; MS (El, 70 eV) m/z (relative intensity, o/o) 
253.1 (M+, 60), 133.1 (25) 121.1 (100) 93.0 (20), 77.0 (IO), 65.0 (30). 
Supplementary material available 
Experimental detail regarding the preparation of all intermediates dis- 
cussed in the synthesis of the above heterocycles is available with the 
online version of this paper. 
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